Pharma & Healthcare Monitor Worldwide
June 20, 2017
Gilead Sciences has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen containing bictegravir (50 mg; BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25mg; F/TAF) for the treatment of HIV-1 infection in adults.
BIC/F/TAF has demonstrated high rates of virologic suppression and no treatment-emergent resistance through 48 weeks in Phase 3 clinical trials among treatment-nave adult patients and among virologically suppressed adult patients who switched regimens.
“We aim to simplify the management of HIV for a broad range of patients with this single tablet regimen that combines the potency of an integrase inhibitor, bictegravir, and the demonstrated long-term safety profile of the F/TAF backbone,” said Norbert Bischofberger, Ph.D., Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences.
This regulatory filing is a demonstration of Gilead’s ongoing commitment to bringing forward treatment innovations that have the potential to address the needs of patients and physicians.
The NDA for BIC/F/TAF is supported by data from four Phase 3 studies in which the regimen met its primary objective of non-inferiority. Three of the ongoing studies are designed to explore the efficacy and safety of BIC/F/TAF compared to triple-therapy regimens containing dolutegravir (50mg; DTG) among treatment-nave patients and among virologically suppressed patients (HIV-1 RNA levels).
Original headline: Gilead submits drug application to FDA for HIV treatment
Copyright 2017 Global Data Point. Provided by Syndigate Media Inc. All Rights Reserved.
Quality News Today is an ASQ member benefit offering quality related news
from around the world every business day.